The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.